作者
Do‐Youn Oh,Aiwu Ruth He,Mohamed Bouattour,Takuji Okusaka,Shukui Qin,Li‐Tzong Chen,Masayuki Kitano,Choong‐kun Lee,Jin Won Kim,Ming-Huang Chen,Salomon M. Stemmer,Masafumi Ikeda,Myung Ah Lee,Jen‐Shi Chen,Piotr Potemski,Howard A. Burris,Vikas Ostwal,Suebpong Tanasanvimon,Chigusa Morizane,Renata Zaucha,Mairéad G. McNamara,Antonio Avallone,Juan Cundom,В. В. Бредер,Benjamin Tan,Satoshi Shimizu,David Tougeron,Ludovic Evesque,Mila Petrova,David B. Zhen,Roopinder Gillmore,Vineet Gupta,Farshid Dayyani,Joon Oh Park,Gary L. Buchschacher,Felipe Rey,Hyosung Kim,Julie Wang,Claire Morgan,Nana Rokutanda,Magdalena Żotkiewicz,Arndt Vogel,Juan W. Valle
摘要
In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine-cisplatin significantly improved overall survival versus placebo plus gemcitabine-cisplatin in participants with advanced biliary tract cancer. We aimed to report updated overall survival and safety data from TOPAZ-1 with additional follow-up and data maturity beyond the interim analysis.
sissiarno
人人为我我为人人
tuanheqi
wanci
yesss
朴实寻真
香蕉觅云
吴彦祖
moxisi
pluto
yanzu
完美世界
皖公网安备34019202002308
